Gen-Probe gets rights to Qualigen's platform:
This article was originally published in Clinica
In what may accelerate its entry into the clinical point-of-care (POC) testing market, nucleic acid test (NAT) maker Gen-Probe has gained exclusive rights to the immunoassay technology behind Qualigen's blood testing system, FastPack. Gen-Probe hopes access to the technology will help it develop a POC NAT system that can identify harmful micro-organisms and genetic mutations, for use in doctors' offices, outpatient clinics and blood screening centres. The San Diego, California firm will pay Qualigen an initial $1m for an 18-month option to license on an exclusive basis.
You may also be interested in...
A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.
The first of around 260 patients for a clinical trial comparing its PB006 natalizumab biosimilar candidate to Biogen’s Tysabri reference brand have been recruited by Polpharma Biologics, which has just added Karsten Roth and Alexandra Moulson to its team.